av Mika Falck-Hansen | okt 29, 2021
Business opportunity Solid tumours are a cause of significant morbidity and mortality. This technology has the possibility to effectively treat a wide variety of advanced stage, solid tumours...
av Helene Dugstad | sep 27, 2021
Our team at Oslo University Hospital and University of Oslo has found a potent immune regulatory microRNA harbouring a potential to treat inflammatory conditions. Osteoarthritis is a common inflammatory joint disease and the specific microRNA represents a novel...
av Aina Rengmark | des 9, 2020
Business opportunity Resistant hypertension (RHT) is a frequent disease and causes premature morbidity and death. RHT is defined as high blood pressure that remains above goal despite the use of three antihypertensive drugs of different classes. The prevalence of...
av Janncike Kristoffersen | aug 5, 2020
Business opportunity Scientists at Oslo University Hospital have developed a potent and specific inhibitor of tankyrase (OM-153), a master regulator of both WNT and YAP signaling pathways. These pathways are involved in the establishment and maintenance of cancer; at...
